{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T02:36:19Z","timestamp":1776479779153,"version":"3.51.2"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.intimp.2014.09.015","type":"journal-article","created":{"date-parts":[[2014,9,22]],"date-time":"2014-09-22T16:19:09Z","timestamp":1411402749000},"page":"442-446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4861-1401","authenticated-orcid":false,"given":"Danielli C.","family":"Bichuetti-Silva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda P.","family":"Furlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda A.","family":"Nobre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila T.M.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tessa R.T.","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Gouveia-Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Rota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lusinete","family":"Tavares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana T.L.","family":"Mazzucchelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz T.","family":"Costa-Carvalho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.intimp.2014.09.015_bb0005","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2249.2011.04387.x","article-title":"Intravenous immunoglobulin in immunodeficiencies: more than mere replacement therapy","volume":"164","author":"Kaveri","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.intimp.2014.09.015_bb0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.beha.2005.01.032","article-title":"Use of intravenous immunoglobulin G (IVIG)","volume":"19","author":"Looney","year":"2006","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.intimp.2014.09.015_bb0015","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1067\/mai.2001.118640","article-title":"Intravenous immunoglobulin consensus statement","volume":"108","author":"Sacher","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.intimp.2014.09.015_bb0020","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1331\/108658002763316888","article-title":"Intravenous immunoglobulins: clinical experience and viral safety","volume":"42","author":"Ballow","year":"2002","journal-title":"J Am Pharm Assoc"},{"key":"10.1016\/j.intimp.2014.09.015_bb0025","first-page":"688","article-title":"Risks and benefits of intravenous immunoglobulin treatment in children","volume":"7","author":"Fasano","year":"1995","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.intimp.2014.09.015_bb0030","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1136\/adc.74.6.527","article-title":"Treatment of hypogammaglobulinaemia with intravenous immunoglobulin, 1973\u201393","volume":"74","author":"Skull","year":"1996","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.intimp.2014.09.015_bb0035","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/BF01541739","article-title":"Surveillance of adverse reactions in patients self-infusing intravenous immunoglobulin at home","volume":"15","author":"Brennan","year":"1995","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.intimp.2014.09.015_bb0040","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0248-8663(03)00137-1","article-title":"Intravenous immunoglobulin (Endobulin) clinical tolerance: prospective therapeutic follow-up of 142 adults and children","volume":"24","author":"Pautard","year":"2003","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.intimp.2014.09.015_bb0045","first-page":"953","article-title":"Adverse reactions of intravenous immunoglobulin","volume":"21","author":"Al Wahadneh","year":"2000","journal-title":"Saudi Med J"},{"key":"10.1016\/j.intimp.2014.09.015_bb0050","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/00043426-200310000-00011","article-title":"Low-dose versus high-dose immunoglobulin for primary treatment of acute immune thrombocytopenic purpura in children: results of a prospective, randomized single-centre trial","volume":"25","author":"Benesh","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"10.1016\/j.intimp.2014.09.015_bb0055","first-page":"139","article-title":"Adverse reactions of prophylactic intravenous immunoglobulin; a 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases","volume":"19","author":"Dashti-Kahavidaki","year":"2009","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.intimp.2014.09.015_bb0060","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10875-012-9656-5","article-title":"Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency","volume":"32","author":"Wasserman","year":"2012","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.intimp.2014.09.015_bb0065","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.autrev.2006.08.011","article-title":"Safety of intravenous immunoglobulin (IVIG) therapy","volume":"6","author":"Katz","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.intimp.2014.09.015_bb0070","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.tmrv.2013.05.004","article-title":"Adverse effects of human immunoglobulin therapy","volume":"27","author":"Stiehm","year":"2013","journal-title":"Transfus Med Rev"},{"issue":"3","key":"10.1016\/j.intimp.2014.09.015_bb0075","first-page":"104","article-title":"I Brazilian Consensus about use of human immunoglobulin in patients with primary immunodeficiency Brazilian Society of Allergy and Immunopathology","volume":"33","author":"Costa-Carvalho","year":"2010","journal-title":"Rev Bras Alerg Imunopatol"},{"issue":"11","key":"10.1016\/j.intimp.2014.09.015_bb0080","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1592\/phco.2005.25.11part2.78S","article-title":"The product: all intravenous immunoglobulins are not equivalent","volume":"25","author":"Siegel","year":"2005","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.intimp.2014.09.015_bb0085","first-page":"1","article-title":"Primary immunodeficiency diseases. Report of a WHO scientific group","volume":"109","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.intimp.2014.09.015_bb0090","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1046\/j.1365-2249.2003.02199.x","article-title":"Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin","volume":"133","author":"Brennan","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.intimp.2014.09.015_bb0095","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2249.2003.02110.x","article-title":"Primary immunodeficiency diseases: an update","volume":"132","author":"Chapel","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.intimp.2014.09.015_bb0100","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000073059","article-title":"Therapy with intravenous immunoglobulins: complications and side-effects","volume":"50","author":"Wittstock","year":"2003","journal-title":"Eur Neurol"},{"key":"10.1016\/j.intimp.2014.09.015_bb0105","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0887-7963(03)00038-5","article-title":"Risks associated with use of intravenous immunoglobulin","volume":"17","author":"Pierce","year":"2003","journal-title":"Transfus Med Rev"},{"issue":"Suppl. 3","key":"10.1016\/j.intimp.2014.09.015_bb0110","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.2146\/ajhp050283","article-title":"Clinical and investigational considerations for the use of IVIG therapy","volume":"62","author":"Ballow","year":"2005","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.intimp.2014.09.015_bb0115","author":"Silvergleid"},{"key":"10.1016\/j.intimp.2014.09.015_bb0120","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/adc.2005.078733","article-title":"A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions","volume":"91","author":"Singh-Grewal","year":"2006","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.intimp.2014.09.015_bb0125","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0002-9343(01)00884-1","article-title":"Primary humoral immunodeficiency (late-onset common variable immunodeficiency) with antinuclear antibodies and selective immunoglobulin deficiency","volume":"111","author":"Andres","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/j.intimp.2014.09.015_bb0130","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1006\/clim.1999.4725","article-title":"Common variable immunodeficiency: clinical and immunological features of 248 patients","volume":"92","author":"Cunningham-Rundles","year":"1999","journal-title":"Clin Immunol"},{"key":"10.1016\/j.intimp.2014.09.015_bb0135","first-page":"285","article-title":"Common variable immunodeficiency: diagnosis and management","volume":"73","author":"Eisenstein","year":"1994","journal-title":"Ann Allergy"},{"key":"10.1016\/j.intimp.2014.09.015_bb0140","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1023\/A:1006650812886","article-title":"IgG anti-IgA subclasses in common variable immunodeficiency and association with severe adverse reactions to intravenous immunoglobulin therapy","volume":"20","author":"de Albuquerque Campos","year":"2000","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.intimp.2014.09.015_bb0145","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/s00415-003-1085-1","article-title":"Side effects of intravenous immunoglobulins in neurological autoimmune disorders\u2014a prospective study","volume":"250","author":"Stangel","year":"2003","journal-title":"J Neurol"},{"key":"10.1016\/j.intimp.2014.09.015_bb0150","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1023\/B:JOCI.0000029108.18995.61","article-title":"Flebogamma 5% Investigators. Safety, efficacy and pharmacokinetics of Flebogamma 5% for replacement therapy in primary immunodeficiency diseases","volume":"24","author":"Berger","year":"2004","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.intimp.2014.09.015_bb0155","series-title":"2014 CIS annual meeting: Primary Immune Deficiency Diseases North American Conference 2014","first-page":"357","article-title":"Evaluation of lipid profile and apolipoprotein A\u2013T: relationship with enzymes associated with cardiovascular risk in patients with hypogammaglobulinaemia","volume":"34","author":"Vieira","year":"2014"},{"issue":"2","key":"10.1016\/j.intimp.2014.09.015_bb0160","first-page":"136","article-title":"Nutricional status and food intake of patients with common variable immunodeficiency","volume":"28","author":"Valente","year":"2013","journal-title":"Rev Bras Nutr Clin"},{"issue":"6","key":"10.1016\/j.intimp.2014.09.015_bb0165","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.jaci.2010.02.040","article-title":"Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22years","volume":"125","author":"Lucas","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.intimp.2014.09.015_bb0170","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.iac.2008.01.008","article-title":"Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency","volume":"28","author":"Berger","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.intimp.2014.09.015_bb0175","author":"IDF"},{"issue":"4","key":"10.1016\/j.intimp.2014.09.015_bb0180","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jaci.2006.01.015","article-title":"Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology","volume":"117","author":"Orange","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.intimp.2014.09.015_bb0185","series-title":"European Society for Immune Deficiency","author":"Fasth","year":"2006"},{"key":"10.1016\/j.intimp.2014.09.015_bb0190","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1067\/mai.2002.129359","article-title":"Are all IGIVs the same?","volume":"110","author":"Gelfand","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.intimp.2014.09.015_bb0195","doi-asserted-by":"crossref","first-page":"494","DOI":"10.2340\/00015555-0900","article-title":"Not all intravenous immunoglobulin preparations are equally well tolerated","volume":"90","author":"Feldemeyer","year":"2010","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.intimp.2014.09.015_bb0200","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1385\/CRIAI:29:3:173","article-title":"Intravenous immunoglobulin. Adverse effects and safe administration","volume":"29","author":"Orbach","year":"2006","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.intimp.2014.09.015_bb0205","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.jaci.2008.08.033","article-title":"Intravenous immunoglobulin: adverse reactions and management","volume":"122","author":"Bonilla","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.intimp.2014.09.015_bb0210","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s15010-012-0323-9","article-title":"Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients","volume":"40","author":"Shroeder","year":"2012","journal-title":"Infection"},{"key":"10.1016\/j.intimp.2014.09.015_bb0215","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/infdis\/156.4.652","article-title":"Self-infusion of intravenous immunoglobulin by immunodeficient patients at home","volume":"156","author":"Ochs","year":"1987","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.intimp.2014.09.015_bb0220","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10875-006-8905-x","article-title":"Health-related quality of life and treatment satisfaction in North American patients with primary immunodeficiency diseases receiving subcutaneous IgG self-infusions at home","volume":"26","author":"Nicolay","year":"2006","journal-title":"J Clin Immunol"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576914003671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576914003671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,29]],"date-time":"2018-09-29T09:57:04Z","timestamp":1538215024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576914003671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S1567576914003671"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2014.09.015","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2014.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}